Phase I dose-escalation trial of intravenous davunetide
Latest Information Update: 16 Feb 2009
Price :
$35 *
At a glance
- Drugs Davunetide (Primary)
- Indications Mild cognitive impairment
- Focus Adverse reactions; Pharmacokinetics
- 08 Nov 2005 New trial record.